Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis

Table 1 Quantitative reverse transcription PCR primer sequences

Gene	Primers	Sequence (5’to 3’)
NLRP3	Forward	GACCGTGAGGAAAGGACCAG
	Reverse	GGCCAAAGAGGAATCGGACA
CASP1	Forward	CGAGGGTTGGAGCTCAAGTT
	Reverse	AGAAGTCTTGTGCTCTGGGC
GSDMD	Forward	TGCTTGAAGGGTGAAGGCAA
	Reverse	CACCTGAGGAGGGCTCAAAG
IL-1β	Forward	ATGCCACCTTTTGACAGTGATG
	Reverse	TGTGCTGCTGCGAGATTTGA
GAPDH	Forward	TCTACATGTTCCAGTATGACTC
	Reverse	ACTCCACGACATACTCAGCACC

NLRP3: NOD-, LRR- and pyrin domain-containing 3; CASP1: Caspase-1; GSDMD: Gasdermin D; IL-1β: Interleukin-1β; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

Table 2 Statistical data of serological indicators

	Control	CCl4	Vehicle	DHM
TC (mmol/L)	1.77 ± 0.12	2.22 ± 0.17a	2.21 ± 0.16a	1.87 ± 0.19c
TG (mmol/L)	0.80 ± 0.13	0.82 ± 0.11	0.72 ± 0.20	0.75 ± 0.20
LDL (mmol/L)	0.12 ± 0.03	0.30 ± 0.04a	0.34 ± 0.11a	0.23 ± 0.01b
HDL (mmol/L)	1.51 ± 0.09	1.44 ± 0.07	1.25 ± 0.28	1.31 ± 0.29
ALT (U/L)	119.87 ± 22.26	367.40 ± 21.15a	415.42 ± 45.03a	213.52 ± 31.82c
AST (U/L)	126.05 ± 25.60	1790.30 ± 376.01a	1995.52 ± 273.80a	615.65 ± 170.62c

^aP < 0.01 vs control group.

^bP < 0.05 vs vehicle group.

^cP < 0.01 vs vehicle group. TC: Total cholesterol; TG: Triglyceride; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.